Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine

McGill COVID19 Vaccine Tracker Team https://covid19.trackvaccines.org/vaccines/

Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. FDA Tides Harvest Pharmaceuticals (Basel). 2018;12:2019. https://doi.org/10.3390/ph12020052.

Lindenboom CR. https://investors.alnylam.com/press-releases(2018).

Pfizer Inc, https://www.pfizer.com/news/press-release/press-releases-archive(2021).

Moderna, Inc. https://investors.modernatx.com/news-releases(2021).

Jain S, Batra H, Yadav P. & Chand S. COVID-19 vaccines currently under preclinical and clinical studies, and associated antiviral immune response. Vaccines 8, https://doi.org/10.3390/vaccines8040649 (2020).

Huang L, et al. SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies. Asian J Pharm Sci. 2020. https://doi.org/10.1016/j.ajps.2020.08.001.

Shin MD, et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol. 2020;15:646–55. https://doi.org/10.1038/s41565-020-0737-y.

Campos EVR, et al. How can nanotechnology help to combat COVID-19? Opportunities and urgent need. J Nanobiotechnol. 2020;18:125. https://doi.org/10.1186/s12951-020-00685-4.

Lundstrom K. The current status of COVID-19 vaccines. Frontiers in Genome Editing 2, https://doi.org/10.3389/fgeed.2020.579297 (2020).

Dong Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy. 2020;5:237. https://doi.org/10.1038/s41392-020-00352-y.

Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–27. https://doi.org/10.1038/s41586-020-2798-3.

Zimmer C, Corum J, Wee. SL. Coronavirus Vaccine Tracker, https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

Fuller DH, Berglund P. Amplifying RNA vaccine development. N Engl J Med. 2020;382:2469–71. https://doi.org/10.1056/NEJMcibr2009737.

Keech C, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320–32. https://doi.org/10.1056/NEJMoa2026920.

JM Reimer et al 2012 Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen PLoS ONE 7 e41451 e41451 https://doi.org/10.1371/journal.pone.0041451

Pharmaceuticals E. Fusogenix https://www.entospharma.com/fusogenix(2020).

Houseley J, Tollervey D. The many pathways of RNA degradation. Cell. 2009;136:763–76. https://doi.org/10.1016/j.cell.2009.01.019.

Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27:710–28. https://doi.org/10.1016/j.ymthe.2019.02.012.

Barenholz Y. Doxil® — the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–34. https://doi.org/10.1016/j.jconrel.2012.03.020.

Lab GCD. https://ourworldindata.org/covid-vaccinations(2020).

Pfizer Inc, Pfizer and BioNTech announce vaccine candidate against covid-19 achieved success in first interim analysis from phase 3 study, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against

Mrinalika Roy TR. Moderna CEO confident of producing 500 million COVID-19 vaccine doses in 2021, https://www.reuters.com/article/us-health-coronavirus-moderna/moderna-ceo-confident-of-producing-500-million-covid-19-vaccine-doses-in-2021-idUSKBN28E2QX(2020).

Vrieze Jd. Suspicions grow that nanoparticles in Pfizer’s COVID-19 vaccine trigger rare allergic reactions. Science Magazine, https://doi.org/10.1126/science.abg2359 (2020).

Diaz A. Boston health care worker who experienced reaction to Moderna coronavirus vaccine has history of allergies, 2020).